CELL INTELLIGENCE · 肿瘤细胞治疗研究

CTLA4 和 LAG3 单核苷酸多态性对接受 BCMA CAR-T 细胞治疗的多发性骨髓瘤患者的临床影响

Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.

T 细胞动力学、CD8/NK 比值及肿瘤生存特征决定骨髓瘤对 T 细胞双特异性抗体 forimtamig 的应答

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

晚期多发性骨髓瘤患者在接受基于 CELMoD 的桥接治疗后，将 cilta-cel 作为第 2 种 CAR-T 细胞疗法，早期即出现深度缓解

Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.

多发性骨髓瘤的治疗决策

Treatment Decisions in Multiple Myeloma.

用于评估 CAR-T 细胞治疗的 3D 工程化多发性骨髓瘤微环境

A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy.

桥接治疗在复发/难治性多发性骨髓瘤患者接受 CAR-T 细胞治疗前的疗效和安全性

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

难治性多发性骨髓瘤抗 BCMA CAR-T 治疗后脊髓神经根压迫的快速消退

Rapid regression of myeloradicular compression following anti-BCMA CAR-T therapy in refractory multiple myeloma.

mezigdomide 降解 Ikaros 减轻 T 细胞功能障碍并提高抗骨髓瘤 T 细胞疗法疗效

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

适应性桥接和维持治疗常降低肿瘤负荷，并与多发性骨髓瘤 CAR-T 细胞治疗后毒性降低相关：单中心真实世界经验

Adaptive Bridging and Holding Therapy Frequently Reduces Tumor Burden and Is Associated With Reduced Toxicity After CAR-T Cell Therapy in Multiple Mye

输注前更深的缓解与 BCMA 靶向 CAR-T 治疗后显著更低的毒性相关，表明输注前的疾病控制是毒性潜在可干预的决定因素。强化等待与桥接策略在高强度预处理患者中可降低疾病负荷，且安全可行，支持通过前瞻性验证以缓解适应性桥接来改善 RRMM 中 CAR-T 治疗的安全性。

ide-cel 和 cilta-cel 在复发/难治性多发性骨髓瘤中的真实世界结局：奥地利全国性、回顾性分析

Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.